LINC01181: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC01181

NCBI ID: G379034

LINC01181

Other Name(s): Long intergenic non-protein coding RNA 1181 | long intergenic non-protein coding RNA 1181

LINC01181: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC01181 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique feature that consists of 19 exons, 18 of which are intergenic, meaning they are located between the intron and the exon. Despite its unique structure, LINC01181 is not a protein, which means it does not have any functional modules, such as a signal transduction domain, protein-protein interaction domains, or a known protein-coding gene.

The discovery and characterization of LINC01181

The LINC01181 gene was first identified in the human transcriptome using RNA-seq technology. The RNA-seq data showed that LINC01181 was expressed in various tissues and cells of the human body, including the brain, heart, liver, and muscle. The expression level of LINC01181 was also shown to be highly correlated with the expression levels of other genes, including known protein-coding genes, non-coding RNA (ncRNA) genes, and microRNAs.

The next step in the characterization of LINC01181 was to determine its function. Using a variety of techniques, such as RNA-seq, microarray, and in vitro transcription assays, researchers found that LINC01181 was involved in various cellular processes, including cell growth, cell differentiation, and cell survival.

One of the most exciting findings from these studies was that LINC01181 was shown to be a negative regulator of the TGF-β pathway, which is a well-known regulator of cell growth and differentiation. The researchers found that LINC01181 was able to inhibit the transcriptional activity of TGF-β, which is associated with numerous diseases, including cancer, neurodegenerative diseases, and developmental disorders.

In addition to its role in the TGF-β pathway, LINC01181 has also been shown to be involved in various other cellular processes, including the cell cycle, apoptosis, and metabolism. These findings have implications for the development of new therapeutic strategies for diseases associated with TGF-β signaling.

The potential as a drug target or biomarker

The unique feature of LINC01181, its role in the TGF-β pathway, and its involvement in various cellular processes make it an attractive drug target or biomarker. If successful, drug development targeting LINC01181 could lead to the development of new treatments for a variety of diseases.

One potential mechanism by which LINC01181 could be targeted is its role in the TGF-β pathway. The TGF-β pathway has been implicated in the development and progression of many diseases, including cancer, neurodegenerative diseases, and developmental disorders. By inhibiting the transcriptional activity of LINC01181, drug developers could potentially target the TGF-β pathway and treat associated diseases.

Another potential mechanism by which LINC01181 could be targeted is its involvement in various cellular processes. LINC01181 has been shown to be involved in cell growth, cell differentiation, apoptosis, and metabolism, which are all critical processes that are affected in many diseases. By targeting LINC01181, drug developers could potentially treat a wide range of diseases that are caused by disruptions in these critical processes.

In addition to its potential as a drug target, LINC01181 has also been shown to be a potential biomarker. The expression of LINC01181 has been shown to be highly correlated with the expression of other genes, including known protein-coding genes, non-coding RNA (ncRNA) genes, and microRNAs. This suggests that LINC01181 could be a useful biomarker for the diagnosis and monitoring of various diseases.

Conclusion

LINC01181 is a long intergenic non-protein-coding RNA that has been identified in various organisms, including humans. Its unique feature is its unique structure, consisting of 19 exons, 18 of which are intergenic. LINC01181 has been shown to be involved in various cellular processes, including

Protein Name: Long Intergenic Non-protein Coding RNA 1181

The "LINC01181 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01181 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets